Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2337010
Max Phase: Preclinical
Molecular Formula: C142H205N35O35
Molecular Weight: 2962.41
Molecule Type: Unknown
Associated Items:
ID: ALA2337010
Max Phase: Preclinical
Molecular Formula: C142H205N35O35
Molecular Weight: 2962.41
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCNC(=O)CCCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CO)C(C)C)C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(=O)O
Standard InChI: InChI=1S/C142H205N35O35/c1-74(2)58-100(165-131(202)105(164-122(193)94(144)70-178)64-86-66-152-95-28-17-15-26-92(86)95)126(197)157-81(12)120(191)170-107(63-85-42-50-91(185)51-43-85)139(210)177-57-25-33-111(177)135(206)154-68-114(187)156-79(10)121(192)174-117(77(7)8)138(209)172-108(71-179)133(204)167-103(61-83-38-46-89(183)47-39-83)129(200)162-98(31-22-54-150-141(145)146)124(195)160-97(30-19-21-53-149-113(186)35-14-13-20-52-143)123(194)161-99(32-23-55-151-142(147)148)125(196)166-104(62-84-40-48-90(184)49-41-84)130(201)171-109(72-180)134(205)175-116(76(5)6)137(208)159-78(9)118(189)155-69-115(188)176-56-24-34-112(176)136(207)169-102(60-82-36-44-88(182)45-37-82)127(198)158-80(11)119(190)163-101(59-75(3)4)128(199)168-106(132(203)173-110(73-181)140(211)212)65-87-67-153-96-29-18-16-27-93(87)96/h15-18,26-29,36-51,66-67,74-81,94,97-112,116-117,152-153,178-185H,13-14,19-25,30-35,52-65,68-73,143-144H2,1-12H3,(H,149,186)(H,154,206)(H,155,189)(H,156,187)(H,157,197)(H,158,198)(H,159,208)(H,160,195)(H,161,194)(H,162,200)(H,163,190)(H,164,193)(H,165,202)(H,166,196)(H,167,204)(H,168,199)(H,169,207)(H,170,191)(H,171,201)(H,172,209)(H,173,203)(H,174,192)(H,175,205)(H,211,212)(H4,145,146,150)(H4,147,148,151)/t78-,79-,80-,81-,94-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,116-,117-/m0/s1
Standard InChI Key: FIKIMEKCDPWXON-KHPWIGICSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2962.41 | Molecular Weight (Monoisotopic): 2960.5337 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, An J, Pasquale EB, Huang Z.. (2013) Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor., 4 (3): [PMID:24167659] [10.1021/ml3004523] |
Source(1):